The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience.
T. Shimizu
No relevant relationships to disclose
A. W. Tolcher
No relevant relationships to disclose
K. P. Papadopoulos
No relevant relationships to disclose
M. Beeram
No relevant relationships to disclose
D. W. Rasco
No relevant relationships to disclose
L. S. Smith
No relevant relationships to disclose
S. Gunn
No relevant relationships to disclose
L. Smetzer
No relevant relationships to disclose
T. A. Mays
No relevant relationships to disclose
B. Kaiser
No relevant relationships to disclose
C. Alvarez
No relevant relationships to disclose
G. L. Mangold
No relevant relationships to disclose
A. Patnaik
No relevant relationships to disclose